549 related articles for article (PubMed ID: 9516951)
1. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
3. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Gandhi V; Estey E; Keating MJ; Plunkett W
J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
[TBL] [Abstract][Full Text] [Related]
6. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
[TBL] [Abstract][Full Text] [Related]
7. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Gandhi V; Kemena A; Keating MJ; Plunkett W
Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
[TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
12. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
[TBL] [Abstract][Full Text] [Related]
14. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
15. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
16. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Gandhi V; Robertson LE; Keating MJ; Plunkett W
Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
[TBL] [Abstract][Full Text] [Related]
17. Re: V.I. Avramis et al., Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin. Cancer Res., 4: 45-52, 1998. Fludarabine: phosphate or no phosphate, that is the confusion.
Bosanquet AG
Clin Cancer Res; 1999 Feb; 5(2):475-6. PubMed ID: 10037200
[No Abstract] [Full Text] [Related]
18. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
[TBL] [Abstract][Full Text] [Related]
19. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Estey E; Plunkett W; Gandhi V; Rios MB; Kantarjian H; Keating MJ
Leuk Lymphoma; 1993 Mar; 9(4-5):343-50. PubMed ID: 8394169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
